Vor Biopharma (NASDAQ:VOR) Posts Earnings Results, Misses Expectations By $0.11 EPS

Vor Biopharma (NASDAQ:VOR) issued its earnings results on Tuesday. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11), Zacks reports.

Vor Biopharma Stock Up 3.1%

Shares of NASDAQ:VOR traded up $0.69 during midday trading on Thursday, reaching $23.03. The company’s stock had a trading volume of 278,318 shares, compared to its average volume of 1,066,530. The firm has a 50 day moving average of $18.18 and a 200-day moving average of $15.91. Vor Biopharma has a 12-month low of $6.50 and a 12-month high of $50.20.

Analyst Upgrades and Downgrades

VOR has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Wedbush upped their price objective on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday. Weiss Ratings upgraded shares of Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a report on Tuesday. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $31.00 price target on shares of Vor Biopharma in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $43.38.

Hedge Funds Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. grew its stake in shares of Vor Biopharma by 172.7% in the 4th quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock worth $70,697,000 after buying an additional 3,422,697 shares during the last quarter. Paradigm Biocapital Advisors LP purchased a new position in Vor Biopharma during the fourth quarter valued at $22,890,000. Caligan Partners LP bought a new stake in Vor Biopharma in the fourth quarter worth $12,100,000. Sphera Funds Management LTD. purchased a new stake in shares of Vor Biopharma in the fourth quarter worth $5,368,000. Finally, Laurion Capital Management LP purchased a new stake in shares of Vor Biopharma in the fourth quarter worth $4,150,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).